July 30, 2014 6:53 AM ET

Pharmaceuticals

Company Overview of Intersect ENT Inc.

Company Overview

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug-eluting implants for patients undergoing sinus surgery to treat chronic sinusitis. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

1555 Adams Drive

Menlo Park, CA 94025

United States

Founded in 2003

146 Employees

Phone:

650-641-2100

Key Executives for Intersect ENT Inc.

Chief Executive Officer
Age: 44
Total Annual Compensation: $334.8K
Chief Operating Officer and Senior Vice President
Age: 52
Total Annual Compensation: $293.2K
Vice President of Sales
Age: 44
Total Annual Compensation: $154.5K
Compensation as of Fiscal Year 2013.

Intersect ENT Inc. Key Developments

Intersect ENT Inc.(NasdaqGM:XENT) added to NASDAQ Composite Index

Intersect ENT Inc. will be added to the NASDAQ Composite Index.

Intersect ENT Inc. Appoints Cynthia L. Lucchese to Board of Directors

Intersect ENT has appointed Cynthia L. Lucchese to the company's board of directors. Lucchese will serve as chair of the audit committee and as a member of the nominating and governance committee. Lucchese most recently served as senior vice president and chief financial officer of Hillenbrand, and as a member of the board of directors of Brightpoint, where she served as chair of the audit committee. Previously, Lucchese was senior vice president and chief financial officer for Thoratec and she held a variety of finance roles, including vice president and treasurer and chief accounting officer at Guidant, now a part of Boston Scientific. She also spent seven years with Eli Lilly and Company and several years with the audit division of Ernst & Young.

Intersect ENT, Inc. Appoints Cynthia L. Lucchese to Board of Directors

Intersect ENT Inc. announced the appointment of Cynthia L. Lucchese to the company's board of directors. Ms. Lucchese will serve as chair of the audit committee and as a member of the nominating and governance committee. Ms. Lucchese most recently served as Senior Vice President and Chief Financial Officer of Hillenbrand Inc. and as a member of the board of directors of Brightpoint Inc.

Similar Private Companies By Industry

Company Name Region
InvaGen Pharmaceuticals, Inc. United States
Stonebridge Pharma LLC United States
Meridian Medical Technologies, Inc. United States
Drug Royalty Trust 3 United States
Arcadia Rx LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intersect ENT Inc., please visit www.intersectent.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.